#USA #New York #Gross Law Firm #URGN #UroGen

Attention UroGen Pharma Ltd. Shareholders

UroGen Pharma Ltd. (NASDAQ: URGN) investors who have experienced financial losses should be aware that The Gross Law Firm has announced a critical class action notice. This notice is particularly relevant for shareholders who acquired shares during the class period from July 27, 2023, to May 15, 2025. The law firm is actively seeking shareholders who are interested in participating in legal proceedings regarding potential recovery for losses incurred during this timeframe.

Case Details

The class action lawsuit is grounded in allegations that UroGen Pharma made various materially false and misleading statements regarding its business operations, particularly concerning the effectiveness of its lead pipeline product, UGN-102, which is central to its development efforts. Legal complaints claim that:

1. The ENVISION clinical study, which UroGen relied upon to support its drug application, was inadequately designed as it did not include a concurrent control arm, undermining its ability to substantiate effectiveness.
2. Consequently, the company faced challenges in demonstrating that the response duration noted in the study could be attributed to UGN-102.
3. UroGen ignored crucial warnings from the FDA about the study design, raising concerns about the potential approval of the New Drug Application (NDA) related to UGN-102.
4. Statements made by the defendants regarding the company's prospects and business operations were misleading and lacked a sound foundation.

These allegations highlight the serious implications they have for shareholders. With UroGen's stock inflated by these potentially deceptive assertions, investors are encouraged to understand their rights and possible routes to recovery.

Important Dates

Shareholders are reminded that the deadline for registering in this class action is July 28, 2025. It's essential to act quickly to safeguard your interests and ensure inclusion in this legal endeavor. Furthermore, being appointed as a lead plaintiff is not necessary to receive any potential recovery; shareholders can still participate without bearing additional responsibilities.

Next Steps for Interested Shareholders

Interested shareholders should take immediate action by registering their information to participate in this class action. By registering, shareholders will gain access to portfolio monitoring software that will provide updates on the case's progress throughout its lifecycle. This affords investors peace of mind and keeps them informed of significant developments.

To secure your place, please follow the link provided by The Gross Law Firm to submit your details:
Register Here

Why Choose The Gross Law Firm?

The Gross Law Firm holds a preeminent position as a nationally recognized class action legal entity. The firm prioritizes the rights of investors who may have suffered due to deceitful practices, fraud, or other unethical business behavior. The firm is staunchly committed to championing corporate accountability and ensuring adherence to responsible business conduct.

Engaging with The Gross Law Firm results in no financial obligation unless recovery is achieved, allowing shareholders a risk-free way to pursue justice.

Conclusion

In conclusion, shareholders of UroGen Pharma Ltd. facing possible financial losses must consider the implications of the class action lawsuit now underway. As The Gross Law Firm navigates this process, those affected can watch for updates and receive ongoing communication about the case. Participation could result in recouping some of the losses incurred, providing a necessary avenue for accountability and restitution in the financial domain.

For further inquiries or assistance, shareholders can reach out to The Gross Law Firm via the contact information below:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: contact@grosslawfirm.com
• - Phone: (646) 453-8903.